AI for value-based care medication management.
OneDose runs medication management across an entire attributed panel. For an organization holding risk, it tracks adherence, runs post-discharge follow-up, and escalates deteriorating patients to a care manager — on every attributed life rather than on the fraction that current staffing can reach.
Under risk, the patient nobody had time to call is not a service gap. It is an unpriced liability sitting on the panel.
Why panel coverage is the whole argument under risk
A risk-bearing organization is accountable for outcomes across an attributed population, not for the patients who happen to make contact. That is the structural difference from fee-for-service, and it changes what "coverage" means.
Medication is where a large share of that risk concentrates, and it is almost entirely unobserved between visits. Whether a patient is taking what was prescribed, whether they stopped because of a side-effect, whether they ever collected the refill — none of it is visible without asking, and asking is a phone call.
So the panel splits into the patients care management can reach and the ones it cannot. The second group is where avoidable deterioration accumulates, and under risk that group is a liability rather than a missed opportunity.
What changes with OneDose?
Coverage across the panel, not the top decile
Contact stops being rationed by staffing. The medium-risk patients — the ones current stratification deprioritizes and the ones large enough in number to matter — are actually contacted.
Adherence becomes observable
Whether patients are taking their medication moves from an assumption to a tracked signal with a reason attached when it slips: side-effect, cost, confusion, or a refill never collected. Those are four different problems with four different fixes.
Care managers work the escalations
Your most expensive resource stops spending its day dialling and starts spending it on the patients an agent surfaced as genuinely deteriorating.
The record is auditable
Every contact and every escalation is logged and attributable — which matters when a payer, a regulator or your own actuary asks what the intervention actually consisted of.
Can you show the ROI before we commit?
Not from a number on this page, and you should be suspicious of a vendor who offers one. OneDose does not publish outcome percentages it cannot attribute to a named deployment, which means we are not going to hand you a readmission-reduction figure sourced to "customer deployments" and invite you to model against it.
What can be evaluated before commitment is the mechanism and the arithmetic on your own panel: how many attributed lives go uncontacted today, what share of your medication-related escalations arrive after the fact, and what a structured contact on each of them would consist of. That is a conversation with your numbers rather than ours, and it is the honest version of this discussion.
Where to go next
The pages below cover the mechanism in detail — what each agent does, and what it deliberately does not.
Frequently asked
- What is AI for value-based care medication management?
- It is software that runs medication management across a whole attributed panel rather than the subset staffing can reach — tracking adherence, running post-discharge follow-up, capturing why a patient stopped taking something, and escalating deterioration to a care manager. Under risk, the patients nobody has capacity to call are where avoidable cost concentrates.
- How does this change what care managers do?
- They stop dialling and start working escalations. The routine contact — check-ins, medication confirmation, repeat attempts to reach someone — runs without them, and what reaches them is a patient an agent has surfaced as genuinely needing attention, with the history attached.
- What outcome improvement should we expect?
- OneDose does not publish outcome figures it cannot attribute to a named deployment, so there is no percentage to quote here honestly. The evaluable question before a commitment is the arithmetic on your own panel: how many attributed lives are uncontacted today, and what structured contact on each would consist of.